These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16269927)

  • 1. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study.
    Chuansumrit A; Wangruangsatid S; Lektrakul Y; Chua MN; Zeta Capeding MR; Bech OM;
    Blood Coagul Fibrinolysis; 2005 Nov; 16(8):549-55. PubMed ID: 16269927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of recombinant activated factor VII for controlling life-threatening bleeding in Dengue Shock Syndrome.
    Chuansumrit A; Tangnararatchakit K; Lektakul Y; Pongthanapisith V; Nimjaroenniyom N; Thanarattanakorn P; Wongchanchailert M; Komwilaisak P
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):335-42. PubMed ID: 15166920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial.
    Sachs B; Delacy D; Green J; Graham RS; Ramsay J; Kreisler N; Kruse P; Khutoryansky N; Hu SS
    Spine (Phila Pa 1976); 2007 Oct; 32(21):2285-93. PubMed ID: 17906567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy.
    Ekert H; Brizard C; Eyers R; Cochrane A; Henning R
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):389-95. PubMed ID: 16788315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome.
    Ozelo MC; Svirin P; Larina L
    Ann Hematol; 2005 Nov; 84(12):816-22. PubMed ID: 16044315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation.
    Pihusch M; Bacigalupo A; Szer J; von Depka Prondzinski M; Gaspar-Blaudschun B; Hyveled L; Brenner B;
    J Thromb Haemost; 2005 Sep; 3(9):1935-44. PubMed ID: 16102099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation.
    Lodge JP; Jonas S; Jones RM; Olausson M; Mir-Pallardo J; Soefelt S; Garcia-Valdecasas JC; McAlister V; Mirza DF;
    Liver Transpl; 2005 Aug; 11(8):973-9. PubMed ID: 16035095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
    Pychyńska-Pokorska M; Moll JJ; Krajewski W; Jarosik P
    Pediatr Crit Care Med; 2004 May; 5(3):246-50. PubMed ID: 15115562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial.
    Bosch J; Thabut D; Albillos A; Carbonell N; Spicak J; Massard J; D'Amico G; Lebrec D; de Franchis R; Fabricius S; Cai Y; Bendtsen F;
    Hepatology; 2008 May; 47(5):1604-14. PubMed ID: 18393319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
    Simpson E; Lin Y; Stanworth S; Birchall J; Doree C; Hyde C
    Cochrane Database Syst Rev; 2012 Mar; (3):CD005011. PubMed ID: 22419303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant activated factor VII increases survival time in a model of incompressible arterial hemorrhage in the anesthetized pig.
    Sapsford W; Watts S; Cooper G; Kirkman E
    J Trauma; 2007 Apr; 62(4):868-79. PubMed ID: 17426541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
    Chuansumrit A; Isarangkura P; Angchaisuksiri P; Sriudomporn N; Tanpowpong K; Hathirat P; Jorgensen LN
    Haemophilia; 2000 Mar; 6(2):61-5. PubMed ID: 10781189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of recombinant activated factor VII to control bleeding in a young child with qualitative platelet disorder: a case report.
    Inagaki M; Mori T; Tsunematsu Y; Ambo H; Kawai Y
    Blood Coagul Fibrinolysis; 2006 Jun; 17(4):317-22. PubMed ID: 16651876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant activated factor VII for acute intracerebral hemorrhage.
    Mayer SA; Brun NC; Begtrup K; Broderick J; Davis S; Diringer MN; Skolnick BE; Steiner T;
    N Engl J Med; 2005 Feb; 352(8):777-85. PubMed ID: 15728810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G; Shafer FE; Rojas P; Seremetis S
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial.
    Kluger Y; Riou B; Rossaint R; Rizoli SB; Boffard KD; Choong PI; Warren B; Tillinger M
    Crit Care; 2007; 11(4):R85. PubMed ID: 17686152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial.
    Raobaikady R; Redman J; Ball JA; Maloney G; Grounds RM
    Br J Anaesth; 2005 May; 94(5):586-91. PubMed ID: 15734783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
    Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
    Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.